SCHEMBL5029862

SCHEMBL5029862

O=C(NCc1cccc(CC2(C(=O)O)CCCO2)c1)OCc1ccc(Cl)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.40
PPARG P37231 2/20 0.39
PPARA Q07869 2/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
GAA P10253 1/20 0.37
P2RX7 Q99572 4/20 0.36
CYP2C19 P33261 3/20 0.36
CYP1A2 P05177 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP2C9 P11712 2/20 0.36
MEN1 O00255 1/20 0.36
CYP2D6 P10635 1/20 0.36
PKM P14618 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTT P42858 2/20 0.36
CYP3A4 P08684 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GALR3 O60755 1/20 0.36
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5037106 0.89 PPARG (0.43) PPARGPPARACYP2C19CYP2C9CYP3A4
SCHEMBL5032892 0.89 PPARG (0.41) PPARGPPARASMN1; SMN2TSHR
SCHEMBL5031938 0.87 TSHR (0.38) PPARGPPARACYP2C19CYP2C9CYP3A4
SCHEMBL5031840 0.84 ALDH1A1 (0.40) PPARGPPARAGAAP2RX7KMT2A
SCHEMBL5034484 0.82 LMNA (0.43) PPARGPPARAGAAP2RX7CYP2C19
SCHEMBL5031811 0.81 PPARG (0.37) EPHX2PPARGPPARATDP1HTT
SCHEMBL5032002 0.79 PPARG (0.45) PPARGPPARAGAACYP2C19CYP1A2
SCHEMBL5034521 0.79 MGLL (0.45) PPARGPPARACYP2C19CYP2C9CYP3A4
SCHEMBL5031759 0.77 PPARG (0.42) PPARGPPARAKMT2AMEN1L3MBTL1
SCHEMBL5031929 0.74 PPARA (0.36) PPARGPPARASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371777-B2 Cyclic compound and PPAR agonist EISAI CO., LTD. (JP) 2008-05-13 US disclosed
US-7371777-B2 Cyclic compound and PPAR agonist EISAI CO., LTD. (JP) 2008-05-13 US disclosed
US-7371777-B2 Cyclic compound and PPAR agonist EISAI CO., LTD. (JP) 2008-05-13 US disclosed
US-20050014833-A1 Cyclic compound and ppar agonist EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-20 US disclosed
EP-1452521-A1 CYCLIC COMPOUND AND PPAR AGONIST Eisai Co., Ltd. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014833-A1 Cyclic compound and ppar agonist PPARA, PPARG, PPARD EPHX2 1057/4885PPARG 2/4885PPARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.